Edition:
India

Evofem Biosciences Inc (EVFM.OQ)

EVFM.OQ on NASDAQ Stock Exchange Capital Market

5.25USD
20 Sep 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$5.25
Open
$5.60
Day's High
$5.81
Day's Low
$5.25
Volume
46,657
Avg. Vol
31,928
52-wk High
$7.23
52-wk Low
$3.20

Latest Key Developments (Source: Significant Developments)

Evofem Biosciences Reports Q2 Loss Per Share Of $0.97
Tuesday, 6 Aug 2019 

Aug 5 (Reuters) - Evofem Biosciences Inc ::EVOFEM BIOSCIENCES REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $0.97.Q2 EARNINGS PER SHARE ESTIMATE $-0.37 -- REFINITIV IBES DATA.AMPHORA NDA RESUBMISSION REMAINS ON TRACK FOR Q4 2019.UNRESTRICTED CASH WAS $50.7 MILLION AT JUNE 30, 2019, AS COMPARED TO $0.2 MILLION AT MARCH 31, 2019.  Full Article

Evofem Biosciences Inc Files Prospectus Relates To Resale Of Up To 13.9 Million Shares Of Co's Common Stock By Selling Securityholders - SEC Filing
Tuesday, 25 Jun 2019 

June 24 (Reuters) - Evofem Biosciences Inc ::EVOFEM BIOSCIENCES INC FILES PROSPECTUS RELATES TO RESALE OF UP TO 13.9 MILLION SHARES OF CO'S COMMON STOCK BY SELLING SECURITYHOLDERS - SEC FILING.  Full Article

Evofem Biosciences Reports Q1 Loss Per Share $0.67
Tuesday, 7 May 2019 

May 7 (Reuters) - Evofem Biosciences Inc ::EVOFEM BIOSCIENCES REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q1 LOSS PER SHARE $0.67.Q1 EARNINGS PER SHARE ESTIMATE $-0.41 -- REFINITIV IBES DATA.  Full Article

Evofem Biosciences Reports Q4 Loss Per Share $0.58
Friday, 1 Mar 2019 

March 1 (Reuters) - Evofem Biosciences Inc ::EVOFEM BIOSCIENCES REPORTS FOURTH QUARTER AND YEAR-END 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q4 LOSS PER SHARE $0.58.Q4 EARNINGS PER SHARE ESTIMATE $-0.43 -- REFINITIV IBES DATA.ALSO EXPLORING AMPHORA'S POTENTIAL BEYOND CONTRACEPTION.UNRESTRICTED CASH WAS $1.3 MILLION AT DECEMBER 31, 2018, AS COMPARED TO $12.1 MILLION AT SEPTEMBER 30, 2018.  Full Article

Evofem Biosciences Q3 Loss Per Share $0.71
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - Evofem Biosciences Inc ::EVOFEM BIOSCIENCES REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q3 LOSS PER SHARE $0.71.Q3 EARNINGS PER SHARE VIEW $-0.37 -- THOMSON REUTERS I/B/E/S.EVOFEM BIOSCIENCES- EXPECTS QUARTERLY CASH BURN TO DECREASE TO APPROXIMATELY $7 TO 9 MILLION DURING Q4 OF 2018.  Full Article

Evofem Biosciences Inc Files For Secondary Offering Of Up To 17 Million Shares - SEC Filing
Saturday, 17 Mar 2018 

March 16 (Reuters) - Evofem Biosciences Inc ::EVOFEM BIOSCIENCES INC FILES FOR SECONDARY OFFERING OF UP TO 17 MILLION SHARES - SEC FILING.  Full Article

Neothetics to pay $1.5 mln‍​‍​ to Evofem Biosciences if deal terminated
Tuesday, 17 Oct 2017 

Oct 17 (Reuters) - Neothetics Inc :Neothetics says if merger agreement with Evofem Biosciences terminated under specified circumstances, co to pay Evofem termination fee of up to $1.5 mln‍​‍​.  Full Article

Neothetics Inc and Evofem Biosciences Inc announce merger agreement to create Women’S health company
Tuesday, 17 Oct 2017 

Oct 17 (Reuters) - Neothetics Inc :Neothetics Inc and Evofem Biosciences, Inc. announce merger agreement to create Women’S health company.Neothetics Inc - ‍privately-held Evofem Biosciences will merge with a wholly-owned subsidiary of Neothetics in an all-stock transaction​.Neothetics - ‍Invesco Asset Management entered securities purchase agreement to acquire additional $20 million of common stock in combined Co​.Neothetics Inc - ‍transactions have been approved by board of directors of both companies​.Neothetics - Neothetics will be renamed Evofem Biosciences and will be under leadership of Evofem Biosciences' CEO Saundra Pelletier​.Neothetics Inc - merger ‍exchange ratio assumes $171.4 million in value of Co's common stock will be issued to Evofem Biosciences stockholders in merger​.Neothetics - current Neothetics stockholders to own about 13% of combined company & current Evofem stockholders to own about 87% of combined company​.Neothetics Inc - ‍merger exchange ratio assumes $28.6 million in value of common stock being retained by Neothetics stockholders​.Neothetics Inc - ‍following merger, company will be led by Saundra Pelletier as chief executive officer​.  Full Article